A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

• ClinicalTrials.gov Identifier: NCT05475184
• Recruitment Status: Not yet recruiting
• First Posted: July 26, 2022
• Last Update Posted: July 26, 2022
• Sponsor: Onconic Therapeutics Inc.
• Information provided by (Responsible Party): Onconic Therapeutics Inc.

Study Description

Brief Summary:

To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer subjects previously treated with a PARP inhibitor

Condition or disease	Intervention/treatment	Phase
Ovarian Cancer	Drug: JPI-547	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 58 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Intervention Model Description: This study will be conducted with subjects with HRD-positive, platinum-resistant, advanced/relapsed ovarian cancer with a history of ARP inhibitor treatment using Simon's optimal two-stage design. When the confirmed response is observed in ≥3 out of 18 subjects who are available for tumor assessment in Stage 1, the subjects will proceed with Stage 2. After additional enrollment of 40 subjects who are available for tumor assessment in Stage 2, the assessment will be conducted to identify that the confirmed response is observed in ≥11 out of the final 58 subjects.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multicenter, Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of JPI-547, a PARP/TNKS Dual Inhibitor in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
• Estimated Study Start Date: August 1, 2022
• Estimated Primary Completion Date: November 2024
• Estimated Study Completion Date: June 2025

Arms and Interventions

Arm	Intervention/treatment
Experimental: JPI-547	Drug: JPI-547; Poly-(ADP-ribose) polymerase (PARP) & tankyrase (TNKS) inhibitor.; The investigational product (IP) will be administered once daily for 28 days (4 weeks) with 1 cycle.; 1 capsule (JPI-547 150 mg) will be administered once daily at the same time (e.g., a fixed time in the morning) in a fasted condition within 2 hours before or after a meal.

Outcome Measures

Primary Outcome Measures :

1. Objective Response Rate(ORR) [ Time Frame: From date of study enroll until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months ]
   To evaluate the objective response rate (ORR) in accordance with the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.

Secondary Outcome Measures :

1. Anti-tumor activity [ Time Frame: From date of study enroll until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months ]
   To evaluate the anti-tumor activity in accordance with RECIST v1.1.

Eligibility Criteria

• Ages Eligible for Study: 19 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Patients with advanced/metastatic high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer*:

  1. who has undergone ≥2 previous chemotherapy regimen;
  2. with confirmed platinum resistance**;
  3. ≥3 month PARP inhibitor treatment history;
  4. confirmed BRCA1/2 mutation *** or HRD ****
• Subjects with at least one measurable lesion in accordance with RECIST v1.1
• Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Subjects with life expectancy ≥12 weeks
• Patients with adequate hematologic, kidney, and liver functions confirmed using the following criteria (retesting of laboratory tests is allowed once during screening)
• Subjects who voluntarily decided to participate in this study after being fully informed and gave informed consent

Exclusion Criteria:

• Subjects who meet any of the following conditions cannot participate in this study:

  1. Subjects with a history of severe drug hypersensitivity or the hypersensitivity to IP and its ingredients or similar drugs
  2. Subjects with dysphagia
  3. Subjects confirmed with the following medical or surgical/procedural history:
• Primary malignant tumor other than ovarian cancer diagnosed or treated within 24 months prior to baseline (individuals with successfully treated cutaneous basal/squamous cell carcinoma are eligible for enrollment)
• Major surgery requiring general anesthesia or respiratory support within 4 weeks prior to baseline (2 weeks for video-assisted thoracoscopic surgery [VATS] or open-and-closed [ONC] surgery)
• Severe cardiovascular disease (e.g., myocardial infarction and unstable angina) that occurred within 24 weeks prior to baseline
• New York Heart Association Class 3 or 4 heart failure within 24 weeks prior to baseline
• Severe cerebrovascular disease observed within 24 weeks prior to baseline
• Pulmonary thrombosis or deep vein thrombosis within 24 weeks prior to baseline, or bronchial asthma, obstructive pulmonary disease, or other serious, life-threatening lung disease (e.g., acute respiratory distress syndrome and lung failure) considered ineligible for study participation
• Infections requiring treatment, such as systemic antibiotics and antivirals, within 2 weeks prior to baseline, or other uncontrolled ≥Grade 3 active infectious diseases
• Symptomatic interstitial lung disease
• Subjects who showed poor recovery from hematologic toxicity in the past chemotherapy (e.g., ≥grade 3 toxicity for ≥4 weeks)
• Bone marrow or stem cell transplantation with high-dose chemotherapy
• Total gastrectomy or total duodenectomy
• Individuals with a history of myelodysplastic syndrome (MDS) or pretreatment cytogenetic test results indicating a risk of MDS/acute myeloid leukemia (AML) 4) Subjects with the following concurrent conditions:
• Subjects with clinically significant symptoms or uncontrolled central nervous system or brain metastases (except when systemic corticosteroid administration was stopped at least 4 weeks prior to baseline and was stable for ≥4 weeks)
• Subjects who have confirmed clinically significant conditions in the electrocardiogram (ECG) according to the investigator's judgment
• Uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg)
• Bleeding diatheses
• Active hepatitis B or C virus infection (patients with hepatitis may participate if HBV DNA and HCV RNA are below the lower limit of detection established by the study site)
• Known human immunodeficiency virus infection (HIV) positive
• Subjects with neurological and psychiatric disorders severe enough to affect the study results according to the investigator's judgment 5) Subjects who have the following drug treatment history:
• Subjects who have received chemotherapy†, immunotherapy (including biologics), hormone therapy, or therapeutic/palliative radiotherapy‡ within 4 weeks prior to baseline
• Subjects who require continuous (≥4 weeks) treatment of systemic corticosteroids equivalent to prednisone >10 mg/day
• Subjects who were treated with antithrombotic drugs, including antiplatelet agents and anticoagulants, within 2 weeks from baseline or are expected to be treated with them during the study period (however, low molecular weight heparin [LMWH]) treatment is allowed)
• Subjects who require continuous administration of non-steroidal anti-inflammatory drugs (NSAIDs), which have high risk of bleeding 6) Pregnant or lactating women, or women of childbearing potential who do not intend to abstain or use appropriate contraceptive methods* during the study period and up to 3 months after IP administration *Appropriate contraception: 7) Subjects who have taken or undergone another IP or investigation device within 4 weeks prior to baseline 8) subjects who are judged by the investigator as ineligible for study participation

Contacts and Locations

Contacts

Contact: Onconictherapeutics; 02-3454-0780; onconictherapeutics@gmail.com

Sponsors and Collaborators

Onconic Therapeutics Inc.

More Information

• Responsible Party: Onconic Therapeutics Inc.
• ClinicalTrials.gov Identifier: NCT05475184
• Other Study ID Numbers: JPI-547-201
• First Posted: July 26, 2022
• Last Update Posted: July 26, 2022
• Last Verified: July 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Ovarian Neoplasms; Carcinoma, Ovarian Epithelial; Endocrine Gland Neoplasms; Neoplasms by Site; Neoplasms; Ovarian Diseases; Adnexal Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Neoplasms, Female; Urogenital Neoplasms; Genital Diseases; Endocrine System Diseases; Gonadal Disorders; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type